

## **ASX ANNOUNCEMENT**

### **Appendix 4C Quarterly Cash Flow Report for the Quarter Ending 30 June 2020**

Farmaforce Limited (“Farmaforce” or “Company”) (ASX:FFC), a contract sales organisation offering innovative solutions to the Australian Pharmaceutical Industry, is pleased to release its Quarterly Activity Report and associated Appendix 4C (Quarterly Cashflow Report) to the market.

#### **Business Activities for the Quarter**

The key highlights are:

- An increase of 23% in receipts from customers for Q4 FY20 when compared with Q4 FY19 (Q4 FY20: \$3,545k; Q4 FY19: \$2,883k);
- An increase of 265% in operating net cash inflows for Q4 FY20. This is an increase of \$1,689K compared to Q4 FY19 (Q4 FY20: net cash inflows of \$1,052k; Q4 FY19: net cash outflows of \$637k);
- The significant increase in the net operating cashflow in Q4 FY20 is largely driven by strong receipt collectability from existing clients and additional receipts from new client contracts that commenced in Q3 FY20, which are now being realised in Q4 FY20;
- During the quarter, the Company repaid \$818k of borrowings (including lease repayments);
- Following a strong performance in Q4 FY20, the Company successfully met its forecast (as detailed in the investor update on 10th March 2020), achieving a gross margin of 24.0% for 2HY FY20. This exceeds the forecasted gross margin for 2HY FY20 of 21.6%, representing a significant achievement for the Company as it continues to expand its operations. This was achieved despite a 6% drop in forecasted revenue due to the impact of COVID-19 pandemic. The Company responded swiftly by taking appropriate cost reduction measures, reflected by it exceeding the forecasted gross margin on revenue for 2HY FY20.

Farmaforce has focused on increasing sales capacity, innovating its business model from fee-for-service to a profit sharing partnering model with its clients, and diversifying its sales reach across more medical specialties.

During the quarter, the Company has progressively realised the positive impact of new contracts and clients won in the previous quarters, which has built a strong pipeline of work and increased cashflow when compared with this time last year. The full impact of this portfolio of work will be realised in FY21.

The Company successfully launched an additional Pharmaceutical sales team to extend services beyond GP sales, which has been the Company’s primary focus during the past two years. Additionally, the sales force team utilisation is at near full capacity and this has contributed significantly to the revenue and gross margin increase.

#### **Payments to Related Parties and their Associates (Refer section 6 of Appendix 4C)**

During the quarter, the Company paid \$994k comprising repayments of the borrowings for \$772k, and the remainder in relation to overhead reimbursements, consulting fees and directors’ remuneration to its related parties and their associates.



## About Farmaforce

Farmaforce Ltd is an ASX-listed organization (ASX:FFC) offering innovative sales, data and medical affairs solutions to the Australian healthcare industry. Since inception in 2014, the company has grown its revenue, clients and staff to become one of the leading service organisations in the growing Australian healthcare sector. More than just a sales force, Farmaforce creates scalable, customised solutions that are on-demand to help clients reach their business goals, avoiding in-house overheads. Farmaforce Ltd is a subsidiary of The iQ Group Global Ltd, which is a core member of The iQ Group Global bioscience investment group, providing specialist life science services to the global biopharmaceutical and investment sectors.

## Contact

Registered office: Level 9, 85 Castlereagh Street, Sydney 2000  
Contact address: Level 3, 333 George Street, Sydney 2000  
Phone: +61 2 8239 5400  
Email: [info@farmaforce.com.au](mailto:info@farmaforce.com.au)  
Website address: [www.farmaforce.com.au](http://www.farmaforce.com.au)

Authorized by: **Dr George Syrmalis, Director, 29th July 2020**

## Appendix 4C

Quarterly cash flow report for entities  
subject to Listing Rule 4.7B

## Name of entity

Farmaforce Limited

## ABN

95 167 748 843

## Quarter ended ("current quarter")

30 June 2020

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	3,545	14,312
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(25)	(561)
(c) advertising and marketing	(4)	(71)
(d) leased assets	-	-
(e) staff costs	(2,370)	(10,497)
(f) administration and corporate costs	(116)	(697)
1.3 Dividends received (see note 3)		
1.4 Interest received		
1.5 Interest and other costs of finance paid	(28)	(183)
1.6 Income taxes paid		
1.7 Government grants and tax incentives	50	50
1.8 Other (provide details if material)		
<b>1.9 Net cash from / (used in) operating activities</b>	<b>1,052</b>	<b>2,353</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) entities		
(b) businesses		
(c) property, plant and equipment	-	(47)
(d) investments	(12)	(40)
(e) intellectual property		
(f) other non-current assets		

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other	-	(406)
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(12)</b>	<b>(493)</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)		
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities		
3.5	Proceeds from borrowings	195	4,141
3.6	Repayment of borrowings	(968)	(5,284)
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)- (Lease payments)	(45)	(296)
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>(818)</b>	<b>(1,439)</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	371	172
4.2	Net cash from / (used in) operating activities (item 1.9 above)	1,052	2,353
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(12)	(493)

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(818)	(1,439)
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	<b>Cash and cash equivalents at end of period</b>	<b>593</b>	<b>593</b>

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	593	371
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>593</b>	<b>371</b>

## 6. Payments to related parties of the entity and their associates

- |   | Current quarter<br>\$A'000 |
|---|----------------------------|
| 6.1 Aggregate amount of payments to related parties and their associates included in item 1 | 982                        |
| 6.2 Aggregate amount of payments to related parties and their associates included in item 2 | 12                         |

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

7. <b>Financing facilities</b> <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	4,000	611
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 <b>Total financing facilities</b>	4,000	611

7.5 **Unused financing facilities available at quarter end** 3,389

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

\$4m working capital facility with The IQ Group Global Limited, the parent entity of Farmaforce. This is an interest free, unsecured loan that matures in December 2024.

8. <b>Estimated cash available for future operating activities</b>	\$A'000
8.1 Net cash from / (used in) operating activities (Item 1.9)	1,052
8.2 Cash and cash equivalents at quarter end (Item 4.6)	593
8.3 Unused finance facilities available at quarter end (Item 7.5)	3,389
8.4 Total available funding (Item 8.2 + Item 8.3)	3,982
8.5 <b>Estimated quarters of funding available (Item 8.4 divided by Item 8.1)</b>	3.79

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A as item 8.5 is greater than 2 quarters

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A as item 8.5 is greater than 2 quarters

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A as item 8.5 is greater than 2 quarters

**Compliance statement**

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 29<sup>th</sup> July 2020

Authorised by: **Dr George Syrmalis, Director**

(Name of body or officer authorising release – see note 4)

**Notes**

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.